Form 4: Tandem Diabetes Director's Equity Activity Update
Insider Transaction Report
Tandem Diabetes Care Director Rebecca B. Robertson reported the vesting of 8,759 restricted stock units into common stock and the grant of 10,220 new restricted stock units.
Summary
- Director Rebecca B. Robertson acquired 8,759 shares of Tandem Diabetes Care Inc. common stock on May 21, 2026, through the vesting of previously granted restricted stock units.
- Robertson was granted 10,220 new restricted stock units (RSUs) on May 20, 2026, which will vest on May 20, 2027.
- Following these transactions, Robertson directly owns 22,542 shares of common stock and 10,220 restricted stock units.
Sentiment
Score: 7
Explanation: StockSavvy.ai views this as a routine insider equity activity, including a new grant, which generally indicates stability and continued alignment of director interests with the company's future.
Positives
- Director Rebecca B. Robertson received a new grant of 10,220 restricted stock units, aligning her interests with long-term shareholder value.
- The vesting of 8,759 restricted stock units into common stock increases the director's direct ownership in the company.
Future Outlook
The 10,220 restricted stock units granted to Director Rebecca B. Robertson on May 20, 2026, are scheduled to vest on their one-year anniversary, May 20, 2027.
Industry Context
StockSavvy.ai notes that insider equity grants and vesting are standard compensation practices across industries, particularly in high-growth sectors like medical devices, to align executive incentives with long-term company performance.
Comparison to Industry Standards
- StockSavvy.ai observes that the grant of restricted stock units (RSUs) as part of director compensation is a common practice among publicly traded companies, including peers in the medical device industry such as Dexcom (DXCM) and Insulet Corporation (PODD), to incentivize long-term commitment and performance.
- The vesting schedule, typically one year for director grants, aligns with standard corporate governance practices for non-employee directors.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Substitute Attorney-in-Fact | Shannon M. Hansen (primary attorney-in-fact) | Jerilyn Laskie | May 20, 2026 | Appointment of a substitute attorney-in-fact for SEC Section 16(a) filings. |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Power of Attorney Delegation | Shannon M. Hansen, acting as attorney-in-fact for multiple individuals including Rebecca B. Robertson, appointed Jerilyn Laskie as a substitute attorney-in-fact for executing and filing Section 16(a) documents with the SEC. | May 20, 2026 | This change streamlines the process for insider transaction filings by providing an additional authorized signatory. |
Stakeholder Impact
- Shareholders: Increased alignment of director's interests with long-term company performance through equity ownership.
Next Steps
- The 10,220 restricted stock units granted on May 20, 2026, are expected to vest on May 20, 2027.
Key Dates
| Date | Description |
|---|---|
| April 19, 2022 | Date of Power of Attorney for Dick P. Allen, Elizabeth A. Gasser |
| April 20, 2022 | Date of Power of Attorney for Peyton R. Howell, Rebecca B. Robertson, John F. Sheridan, Christopher J. Twomey, Leigh A. Vosseller |
| April 21, 2022 | Date of Power of Attorney for Ricky A. Carpenter, Kathleen McGroddy-Goetz, Susan M. Morrison, Rajwant S. Sodhi |
| June 15, 2022 | Date of Power of Attorney for Myoungil Cha, Joao Malagueira |
| June 21, 2024 | Date of Power of Attorney for Jean-Claude Kyrillos |
| November 11, 2025 | Date of Power of Attorney for Sandra W. Beaver |
| May 21, 2025 | Grant date for 8,759 RSUs that vested on May 21, 2026 |
| May 20, 2026 | Grant date for 10,220 RSUs |
| May 20, 2026 | Date of execution for Substitute Power of Attorney |
| May 21, 2026 | Transaction date for RSU vesting and common stock acquisition |
| May 22, 2026 | Signature date of reporting person |
| May 20, 2027 | Vesting date for 10,220 RSUs granted on May 20, 2026 |
Recommendation
holdThis Form 4 details routine insider equity compensation, including a new RSU grant and the vesting of previous units. Such transactions are standard and do not provide new fundamental information to warrant a change in investment thesis, thus a 'hold' recommendation is appropriate.
Keywords
TNDM, Tandem Diabetes Care, Form 4, Insider Transaction, Stock Grant, RSU, Director Equity, Rebecca B. Robertson
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.